Kallikrein Activation and Its Association with NT-proBNP, Cystatin C–Derived eGFR, and Cardiac Remodeling in Patients with Chronic Heart Failure and Early Cardiorenal Syndrome
Keywords:
chronic heart failure, cardiorenal syndrome, kallikrein, NT-probnp, cystatin C, estimated glomerular filtration rate, cardiac remodeling, mineralocorticoid receptor antagonistsAbstract
Background: Neurohormonal activation plays a central role in the progression of chronic heart failure (CHF) and in the development of cardiorenal syndrome (CRS). However, the role of the kallikrein–kinin system in early CRS remains insufficiently investigated.
Objective: To evaluate the association between serum kallikrein concentrations and NT-proBNP, cystatin C–derived estimated glomerular filtration rate (eGFR), and cardiac remodeling parameters in patients with New York Heart Association (NYHA) class III CHF and early CRS, and to assess the effect of guideline-directed medical therapy.
Methods: This study included 85 patients with NYHA class III CHF (mean age 66.7 ± 1.0 years) and 40 healthy controls. Patients were stratified according to left ventricular ejection fraction (LVEF ≥40% and <40%). Serum kallikrein, NT-proBNP, aldosterone, and cystatin C concentrations were measured, and eGFR was calculated using the CKD-EPI cystatin C equation. Correlations were evaluated, and biomarker dynamics were reassessed after six months of four-component guideline-directed medical therapy.
Results: Patients with LVEF <40% had significantly lower kallikrein concentrations (448.6 ± 9.6 vs. 581.0 ± 10.7 ng/mL; P < 0.001), higher NT-proBNP concentrations (1123.3 ± 77.7 vs. 547.8 ± 46.5 pg/mL; P < 0.001), and lower eGFR (47.3 ± 0.8 vs. 56.2 ± 1.1 mL/min/1.73 m²; P < 0.001) than patients with LVEF ≥40%. Kallikrein correlated positively with eGFR (r = 0.55; P < 0.001) and inversely with NT-proBNP (r = −0.51; P < 0.001). After six months of therapy, kallikrein concentrations increased significantly and cardiac and renal parameters improved, with a more pronounced effect in patients receiving eplerenone.
Conclusion: Serum kallikrein is associated with both cardiac and renal function in early cardiorenal syndrome and may serve as a candidate biomarker of neurohormonal adaptation and therapeutic response in patients with chronic heart failure.
References
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. doi:10.1002/ejhf.1858.
Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840-e878. doi:10.1161/CIR.0000000000000664.
Savira F, Magaye R, Liew D, Reid C, Kelly DJ, Kompa AR, Sangaralingham SJ, Burnett JC, Kaye D, Wang BH. Cardiorenal syndrome: multi-organ dysfunction involving the heart, kidney and vasculature. Br J Pharmacol. 2020;177(13):2906-2922. doi:10.1111/bph.15065.
Silva Lopez DE, Calzada Delgado HZ, Junez Villicana IL, et al. Cardio-renal syndrome: a comprehensive review of pathophysiology, clinical subtypes, diagnostic challenges, and therapeutic strategies. Int J Med Sci Clin Res Stud. 2025;5(7):1150-1157. doi:10.47191/ijmscrs/v5-i07-21.
Khandait H, Sodhi SS, Khandekar N, Bhattad VB. Cardiorenal syndrome in heart failure with preserved ejection fraction: insights into pathophysiology and recent advances. Cardiorenal Med. 2025;15(1):41-60. doi:10.1159/000542633.
Mohammadi K, Shafie D, Ghomashi N, Abdolizadeh A, Sadeghpour M. Kinin-kallikrein system: new perspectives in heart failure. Heart Fail Rev. 2024;29(3):729-737. doi:10.1007/s10741-024-10393-y.
Gembillo G, Visconti L, Giusti M, Siligato R, Gallo A, Santoro D, Mattina A. Cardiorenal syndrome: new pathways and novel biomarkers. Biomolecules. 2021;11(11):1581. doi:10.3390/biom11111581.
Goffredo G, Barone R, Di Terlizzi V, Correale M, Brunetti ND, Iacoviello M. Biomarkers in cardiorenal syndrome. J Clin Med. 2021;10(15):3433. doi:10.3390/jcm10153433.
Okamoto R, Ali Y, Hashizume R, Suzuki N, Ito M. BNP as a major player in the heart-kidney connection. Int J Mol Sci. 2019;20(14):3581. doi:10.3390/ijms20143581.
Girolami J, Bouby N, Richer-Giudicelli C, Alhenc-Gelas F. Kinins and kinin receptors in cardiovascular and renal diseases. Pharmaceuticals (Basel). 2021;14(3):240. doi:10.3390/ph14030240.
Bekassy Z, Fagerstrom IL, Bader M, Karpman D. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Nat Rev Immunol. 2022;22(7):411-428. doi:10.1038/s41577-021-00634-8.
Gallo G, Lanza O, Savoia C. New insight in cardiorenal syndrome: from biomarkers to therapy. Int J Mol Sci. 2023;24(6):5089. doi:10.3390/ijms24065089.
Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, Tang WHW, Droogne W, Mullens W. Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiol. 2019;74(2):100-107. doi:10.1080/00015385.2018.1455947.
Chen TH, Ou SM, Lin KH, Ho Y, Tseng WC, Chu YC, Tarng DC. Effect of spironolactone on cardiovascular and renal outcomes in patients with chronic kidney disease. Clin Kidney J. 2025;18(9):sfaf247. doi:10.1093/ckj/sfaf247.
Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-161. doi:10.1093/eurheartj/ehaa736.
Lu T, Zhu W, Yang F, Zhu K, Ren J, Zhu H, Ye B, Sun F, Zhang W, Qiu X. Kallikrein-kinin system as a potential target for the treatment of intervertebral disc degeneration. Eur J Med Res. 2025;30(1):1083. doi:10.1186/s40001-025-03341-5.
Cannavo A, Bencivenga L, Liccardo D, Elia A, Marzano F, Gambino G, D'Amico ML, Perna C, Ferrara N, Rengo G, Paolocci N. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid Med Cell Longev. 2018;2018:1204598. doi:10.1155/2018/1204598.
Davel AP, Jaffe IZ, Tostes RC, Jaisser F, Belin de Chantemele EJ. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects. Am J Physiol Heart Circ Physiol. 2018;315(4):H989-H999. doi:10.1152/ajpheart.00073.2018.
Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6(6):489-498. doi:10.1016/j.jchf.2018.02.004.
Lee W, Liao T, Chen T, Fang H, Fang Y, Chen H, Lin Y, Chang S, Chen M. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease. Cardiovasc Drugs Ther. 2023;38(3):505-515. doi:10.1007/s10557-022-07421-0.
Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, Cobble ME, McCullough PA. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99. doi:10.1186/s12933-019-0903-4.
Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, Di Salvo J, Epifani R, Marfella R, Docimo G, Lettieri M, Sardu C, Sasso FC. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23(7):3651. doi:10.3390/ijms23073651.
DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021;17(5):319-334. doi:10.1038/s41581-021-00393-8.
Benoit SW, Ciccia EA, Devarajan P. Cystatin C as a biomarker of chronic kidney disease: latest developments. Expert Rev Mol Diagn. 2020;20(10):1019-1026. doi:10.1080/14737159.2020.1768849.
Chen DC, Potok OA, Rifkin D, Estrella MM. Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR. Kidney360. 2022;3(10):1807-1814. doi:10.34067/KID.0003202022.
Prowle JR, Croal B, Abbott TEF, Cuthbertson BH, Wijeysundera DN, Myles PS, et al. Cystatin C or creatinine for pre-operative assessment of kidney function and risk of post-operative acute kidney injury: a secondary analysis of the METS cohort study. Clin Kidney J. 2024;17(1):sfae004. doi:10.1093/ckj/sfae004.
Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, Tang WHW, Skouri H, Verbrugge FH, Orso F, Hill L, Ural D, Lainscak M, Rossignol P, Metra M, Mebazaa A, Seferovic P, Ruschitzka F, Coats A. Evaluation of kidney function throughout the heart failure trajectory: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(4):584-603. doi:10.1002/ejhf.1697.
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020;97(6):1117-1129. doi:10.1016/j.kint.2020.02.010.
Boulet J, Mehra MR. Left ventricular reverse remodeling in heart failure: remission to recovery. Struct Heart. 2021;5(5):466-481. doi:10.1080/24748706.2021.1954275.
Kang E, Lee SW, Ryu H, Kang M, Kim S, Park SK, Jung JY, Lee K, Han SH, Ahn C, Oh KH. Left ventricular diastolic dysfunction and progression of chronic kidney disease: analysis of KNOW-CKD data. J Am Heart Assoc. 2022;11(13):e025554. doi:10.1161/JAHA.122.025554.
Yang Y, Li Z, Guo X, Zhou Y, Chang Y, Yang H, Yu S, Ouyang N, Chen S, Sun G, Hua Y, Sun Y. Interventricular septum thickness for the prediction of coronary heart disease and myocardial infarction in a hypertension population: a prospective study. J Clin Med. 2022;11(23):7152. doi:10.3390/jcm11237152.
Tile BM, Kumar KS, Sundar R, Kumar P. Echocardiographic assessment of left ventricular diastolic dysfunction in chronic kidney disease. Eur J Cardiovasc Med. 2024;14(6):181-190. doi:10.5083/ejcm.
Ahn JM, Zimmermann FM, Arora S, et al. Prognostic value of comprehensive intracoronary physiology assessment early after heart transplantation. Eur Heart J. 2021;42(48):4918-4929. doi:10.1093/eurheartj/ehab568.
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Sacubitril-valsartan in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-1620. doi:10.1056/NEJMoa1908655.
Wang K, Ni G, Wu Q, Zhou Y, Yao W, Zhang H, Li X. Prognostic value of N-terminal pro-B-type natriuretic peptide and glomerular filtration rate in patients with acute heart failure. Front Cardiovasc Med. 2020;7:123. doi:10.3389/fcvm.2020.00123.
Vergani M, Cannistraci R, Perseghin G, Ciardullo S. The role of natriuretic peptides in the management of heart failure with a focus on the patient with diabetes. J Clin Med. 2024;13(20):6225. doi:10.3390/jcm13206225.
